Clinical TrialJun 12, 2026, 07:02 AM
Kymera KT-621 Phase 1 data in Japanese adults consistent; Phase 2b ongoing
AI Summary
Kymera Therapeutics announced new data from its Phase 1 study of KT-621, an oral STAT6 degrader, in healthy Japanese adults, presented at the JDA Annual Meeting. The results showed consistent safety and pharmacokinetic/pharmacodynamic (PK/PD) profiles, including rapid and sustained STAT6 degradation, comparable to previous studies in non-Japanese adults and atopic dermatitis patients. This data supports KT-621's potential for chronic Type 2 inflammatory diseases. The company's parallel Phase 2b trials for KT-621 in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027, respectively.
Key Highlights
- KT-621 Phase 1 study in healthy Japanese adults presented at JDA.
- Safety and PK/PD results consistent with prior KT-621 clinical studies.
- Demonstrated rapid, sustained STAT6 degradation, median ">=98%" at Day 7.
- KT-621 was well tolerated with a favorable safety profile across doses.
- Parallel Phase 2b trials for atopic dermatitis ongoing, data by mid-2027.
- Parallel Phase 2b trials for asthma ongoing, data by late 2027.
Price Impact
More from KYMR